Label Changes for:

Mobic (meloxicam) Tablets and Oral Suspension

August 2011

Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2011

 

WARNINGS AND PRECAUTIONS

Co-administration with Kayexalate (sodium polystyrene sulfonate)
  • Concomitant use of sorbitol with Kayexalate (sodium polystyrene sulfonate) has been implicated in cases of intestinal necrosis (possibly fatal). Due to the presence of sorbitol in Mobic Oral Suspension, use with Kayexalate is not recommended.

DRUG INTERACTIONS

Kayexalate (sodium polystyrene sulfonate)
  • Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and Kayexalate (sodium polystyrene sulfonate). Due to the presence of sorbitol in Mobic Oral Suspension, use with Kayexalate is not recommended.
Hide
(web4)